Paul McKenna's virtual gastric band is a hypnotherapy-based programme that aims to help people manage their weight by changing eating behaviours at a subconscious level — without any surgical procedure. Developed by British hypnotist Paul McKenna, it uses guided hypnosis, cognitive behavioural principles, and neuro-linguistic programming to encourage smaller portion sizes and a healthier relationship with food. While it may complement broader lifestyle efforts, it is not endorsed by NICE as a standalone weight management treatment and should not be confused with surgical gastric banding. This article explains how the technique works, how it compares with NHS-approved treatments, and when to seek medical advice.

What Is the Paul McKenna Virtual Gastric Band Technique?

The Paul McKenna Virtual Gastric Band is a hypnotherapy programme using guided hypnosis to encourage smaller portion sizes and behavioural change around eating; it is not a medical procedure and has not been endorsed by NICE as a standalone weight management intervention.

The Paul McKenna Virtual Gastric Band is a hypnotherapy-based programme designed to help individuals manage their weight by changing their relationship with food and eating behaviours. Developed by British hypnotist and self-help author Paul McKenna, the technique uses guided hypnosis to encourage behavioural changes around eating — without any physical procedure taking place. The aim is to promote feelings of fullness after consuming smaller portions by targeting habitual thought patterns at a subconscious level. It is important to understand that this is a behavioural approach; it does not produce any physiological restriction of the stomach and should not be compared with surgical gastric banding in terms of mechanism or effect.

The programme is typically delivered through a combination of audio recordings, books, and live or recorded hypnotherapy sessions. It draws on principles from cognitive behavioural therapy (CBT) and clinical hypnosis, as well as neuro-linguistic programming (NLP). It should be noted that NLP lacks a robust evidence base for weight management, and its inclusion does not confer additional clinical credibility to the programme. The behavioural and habit-change elements are the more clinically recognised components.

Hypnotherapy is not a statutorily regulated profession in the UK. This means that, unlike medicine or nursing, there is no legal requirement for practitioners to hold a specific qualification. Individuals seeking a hypnotherapist should look for practitioners registered with a Professional Standards Authority (PSA)–accredited register, such as the Complementary and Natural Healthcare Council (CNHC) or the National Hypnotherapy Society, which require members to meet defined standards of training and practice.

The Virtual Gastric Band is not a medical procedure and is not regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It has not been endorsed by the National Institute for Health and Care Excellence (NICE) as a standalone weight management intervention and is considered a complementary approach rather than a clinically validated treatment. Results vary considerably between individuals, and the programme is not a substitute for evidence-based medical care — particularly for those with obesity-related health conditions such as type 2 diabetes, hypertension, or obstructive sleep apnoea.

How Hypnotherapy May Support Weight Management

Hypnotherapy may offer modest adjunctive benefit for weight management by targeting emotional eating, stress, and motivation, but there is no robust evidence it produces clinically significant weight loss on its own.

Hypnotherapy works by inducing a state of focused relaxation — sometimes described as a trance — during which suggestions are introduced aimed at modifying behaviour and thought patterns. In the context of weight management, these suggestions may target emotional eating, portion control, motivation to be physically active, and the development of a healthier self-image. The underlying rationale is that some unhelpful eating behaviours are driven by habitual patterns that may be more accessible to change during a hypnotic state.

Some small-scale studies and systematic reviews have suggested that hypnotherapy, when used alongside dietary and behavioural interventions, may offer modest additional benefit for weight loss compared with those interventions alone. However, the overall quality of evidence remains limited. Research in this area is frequently hampered by small sample sizes, lack of control groups, heterogeneous populations, and difficulty in standardising hypnotherapy protocols across studies. There is no robust, large-scale clinical trial evidence that hypnotherapy alone produces clinically significant or sustained weight loss. Any benefits should be understood as adjunctive to — not a replacement for — evidence-based dietary, physical activity, and behavioural programmes.

Hypnotherapy may offer indirect benefits that support a broader weight management strategy:

• Reducing stress and anxiety, which are known drivers of emotional and binge eating

• Improving sleep quality, which has a well-established link to appetite regulation and metabolic health

• Enhancing motivation and self-efficacy, which are important psychological factors in sustaining lifestyle changes

• Addressing negative body image, which can act as a barrier to engaging with exercise or dietary programmes

If you suspect you have an eating disorder — such as binge eating disorder, bulimia nervosa, or significant food-related anxiety — it is important to seek assessment from a specialist service before undertaking hypnotherapy. In such cases, hypnotherapy should only be considered as an adjunct under appropriate professional guidance, not as a primary treatment.

For individuals who find conventional approaches difficult to sustain, hypnotherapy may serve as a useful complement to a broader plan. If you choose to work with a hypnotherapist, look for practitioners registered with a PSA-accredited register such as the CNHC or the National Hypnotherapy Society. The NHS also provides an overview of hypnotherapy, including guidance on what to expect and how to find a reputable practitioner.

Comparing Hypnotherapy With NHS Weight Loss Treatments

NHS-approved treatments — including orlistat, GLP-1 receptor agonists such as semaglutide (Wegovy), and bariatric surgery — have a robust evidence base and NICE endorsement that hypnotherapy programmes have not achieved.

NHS weight management services are grounded in interventions with a robust evidence base, including structured dietary programmes, physical activity guidance, behavioural support, pharmacotherapy, and bariatric surgery. These approaches are evaluated and recommended by NICE based on clinical trial data, cost-effectiveness analyses, and long-term outcome evidence — a standard that hypnotherapy-based programmes such as the Paul McKenna Virtual Gastric Band have not met.

Pharmacological treatments currently approved in the UK include orlistat and the GLP-1 receptor agonists semaglutide (Wegovy) and liraglutide (Saxenda). These medicines are subject to MHRA approval and are prescribed within defined NICE eligibility criteria; suitability is determined by a clinician on an individual basis. As approvals and commissioning arrangements evolve, readers are advised to check current NICE guidance and discuss options with their GP or specialist.

• Orlistat works by reducing the absorption of dietary fat in the gut. Prescription-strength orlistat (120 mg, brand name Xenical) requires a prescription. A lower-dose version (60 mg, brand name alli) is available as a Pharmacy (P) medicine, meaning it can be purchased from a pharmacy without a prescription but requires assessment and advice from a pharmacist before supply. Common side effects include oily or fatty stools, oily spotting on underwear, and increased frequency of bowel movements, particularly if a high-fat diet is consumed. Orlistat can also reduce the absorption of fat-soluble vitamins (A, D, E, and K).

• Semaglutide (Wegovy) and liraglutide (Saxenda) are GLP-1 receptor agonists that reduce appetite and slow gastric emptying. In the STEP clinical trials, semaglutide produced an average weight reduction of approximately 15% of body weight over 68 weeks — however, this was achieved alongside a reduced-calorie diet and increased physical activity, and results in routine clinical practice may differ. Common side effects of GLP-1 receptor agonists include nausea, vomiting, diarrhoea, and constipation, particularly when starting treatment. There is also an increased risk of gallstones. These medicines are not recommended during pregnancy or breastfeeding. Eligibility for NHS prescribing follows specific NICE criteria and local commissioning pathways.

If you experience an unexpected or concerning side effect from any medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Surgical options, such as laparoscopic gastric banding, sleeve gastrectomy, and Roux-en-Y gastric bypass, remain the most effective long-term interventions for severe obesity. NICE guidance (CG189) recommends bariatric surgery for adults with a BMI of 40 kg/m² or above, or 35 kg/m² or above with a significant obesity-related condition, when other interventions have not achieved adequate weight loss. NICE also notes that bariatric surgery may be considered for adults with a BMI of 30–34.9 kg/m² who have recent-onset type 2 diabetes, where this is assessed as the most clinically appropriate option.

In contrast, the Virtual Gastric Band carries no surgical risks, requires no recovery period, and is considerably less expensive — but it also lacks the physiological mechanisms that underpin the effectiveness of medical and surgical treatments. It may be most appropriately considered as a complementary tool for individuals with mild to moderate weight concerns, rather than a replacement for clinically indicated interventions.

When to Speak to Your GP About Weight Management Options

Speak to your GP if your BMI is 30 kg/m² or above, you have an obesity-related condition, have tried multiple approaches without success, or experience symptoms of disordered eating.

Weight management is a complex, multifactorial issue, and it is important that individuals seek professional guidance rather than relying solely on self-directed programmes. Speaking to your GP is particularly important in the following circumstances:

• Your BMI is 30 kg/m² or above (or 27.5 kg/m² or above if you are from a South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean background, where health risks occur at lower BMI thresholds)

• You have an obesity-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, non-alcoholic fatty liver disease, or joint problems

• You have tried multiple weight loss approaches without achieving or maintaining meaningful results

• You experience symptoms of disordered eating, such as binge eating, purging, or significant food-related anxiety — these require specialist psychological assessment and support. The charity Beat (beateatingdisorders.org.uk) provides information and support for people affected by eating disorders in the UK

• You are considering weight loss medication or surgery and wish to understand your eligibility under NHS criteria

• You are pregnant, planning a pregnancy, or breastfeeding — weight loss medicines are not recommended during pregnancy or breastfeeding, and tailored advice from your GP or midwife is essential

Your GP can carry out a full clinical assessment, including relevant blood tests, blood pressure measurement, and a review of your medical history and current medications. Waist circumference may also be measured alongside BMI, as it provides additional information about cardiometabolic risk — particularly in individuals from higher-risk ethnic groups. Your GP can also refer you to NHS Tier 2 or Tier 3 weight management services, which provide structured, multidisciplinary support tailored to your individual needs.

While there is no established link between hypnotherapy programmes and adverse medical outcomes in the general population, individuals with a history of psychosis, dissociative disorders, or severe mental illness should consult a mental health professional before undertaking hypnotherapy of any kind. Being transparent with your GP about all approaches you are using — including complementary therapies — ensures that your care is coordinated and safe.

NHS and NICE-Approved Pathways for Long-Term Weight Loss

The NHS provides a four-tier weight management pathway — from public health resources and structured lifestyle programmes through to specialist multidisciplinary services and bariatric surgery — matched to individual clinical need.

The NHS offers a structured, tiered approach to weight management, designed to match the level of clinical support to an individual's needs and health risks. Understanding these pathways can help individuals make informed decisions about the most appropriate route for their circumstances.

Tier 1 involves universal public health interventions, such as the NHS Better Health campaign, which provides free tools, apps, and resources to support healthier eating and increased physical activity. The NHS Digital Weight Management Programme offers a 12-week online behavioural support programme for adults with a BMI of 30 kg/m² or above (or 27.5 kg/m² or above for eligible ethnic groups) who also have type 2 diabetes or hypertension.

Tier 2 services provide more intensive, structured weight management support, typically delivered by dietitians, health coaches, and exercise specialists. These programmes focus on sustainable lifestyle change through dietary education, physical activity, and behavioural strategies.

Tier 3 specialist weight management services are multidisciplinary and designed for individuals with complex obesity, often as a prerequisite to bariatric surgery. They may include psychological support, medical management, and intensive dietary intervention.

Tier 4 encompasses bariatric surgery, which is commissioned by NHS England and subject to NICE eligibility criteria as outlined in guideline CG189.

NICE guidance on obesity and weight management is periodically reviewed and updated to reflect new evidence, including the growing evidence base for newer pharmacological agents such as GLP-1 receptor agonists. Readers are advised to check the current NICE guidance at nice.org.uk and discuss the most up-to-date options with their GP or a specialist, as eligibility criteria and commissioning arrangements may change.

In summary, while approaches such as the Paul McKenna Virtual Gastric Band may offer psychological support and complement broader lifestyle efforts, they should be viewed within the context of a comprehensive, evidence-based weight management plan. Engaging with NHS services ensures access to clinically validated, safe, and personalised care for long-term health outcomes.

Frequently Asked Questions